Table 2 Comorbidities in patients with IPF from the EMPIRE Registry
Prevalence | Incidence | |||
|---|---|---|---|---|
Comorbidity | Patients, n (%) (N = 3580) | Range across participating countries, % | Patients, n (%) (N = 3580) | Range across participating countries, % |
Cardiovascular | 2646 (73.9) | 66.6–82.4 | 2377 (66.4) | 53.3–82.4 |
Arterial hypertension | 1896 (53.0) | 42.5–64.7 | 1645 (45.9) | 33.2–64.7 |
Coronary heart disease | 834 (23.3) | 8.5–35.8 | 691 (19.3) | 7.8–33.3 |
Pulmonary hypertension | 418 (11.7) | 4.4–40.4 | 362 (10.1) | 4.0–40.4 |
Arrhythmias | 378 (10.6) | 3.9–23.5 | 344 (9.6) | 2.6–23.5 |
Heart attack | 213 (5.9) | 0.0–11.8 | 190 (5.3) | 0.0–11.4 |
Embolism | 199 (5.6) | 0.0–10.1 | 177 (4.9) | 0.0–8.9 |
Stroke | 156 (4.4) | 0.0–10.3 | 140 (3.9) | 0.0–10.3 |
Valve disease | 154 (4.3) | 0.3–11.8 | 135 (3.8) | 0.0–11.8 |
Ischaemic disease of the lower limbs | 82 (2.3) | 0.0–4.3 | 74 (2.1) | 0.0–3.7 |
Cardiomyopathy | 44 (1.2) | 0.0–6.5 | 38 (1.1) | 0.0–5.9 |
Other | 380 (10.6) | 3.9–16.3 | 317 (8.9) | 3.5–15.6 |
Pulmonary | 1396 (39.0) | 5.9–68.5 | 1065 (29.7) | 5.9–58.7 |
Emphysema | 365 (10.2) | 0.0–40.6 | 125 (3.5) | 0.0–26.9 |
Tuberculosis | 243 (6.8) | 0.0–29.6 | 63 (1.8) | 0.0–4.3 |
COPD | 235 (6.6) | 0.0–22.1 | 210 (5.9) | 0.0–21.2 |
Respiratory infection | 231 (6.5) | 0.0–12.5 | 229 (6.4) | 0.0–12.4 |
Respiratory insufficiency | 230 (6.4) | 0.0–21.2 | 194 (5.4) | 0.0–21.2 |
Asthma | 160 (4.5) | 0.0–9.6 | 127 (3.5) | 0.0–7.8 |
Lung cancer | 128 (3.6) | 0.9–7.4 | 93 (2.6) | 0.9–6.7 |
Pneumonia | 116 (3.2) | 0.0–6.7 | 104 (2.9) | 0.0–6.5 |
Obstructive sleep apnoea | 99 (2.8) | 0.0–17.1 | 92 (2.6) | 0.0–16.7 |
Other | 246 (6.9) | 0.0–17.6 | 160 (4.5) | 0.0–6.5 |
Gastrointestinal/metabolic | 2119 (59.2) | 28.1–92.3 | 1839 (51.4) | 27.5–88.6 |
Diabetes mellitus | 860 (24.0) | 15.2–37.0 | 762 (21.3) | 14.2–36.6 |
Hyperlipidaemia | 843 (23.5) | 0.0–72.8 | 720 (20.1) | 0.0–67.9 |
Gastroesophageal reflux | 755 (21.1) | 8.5–54.8 | 639 (17.8) | 8.4–51.0 |
Thyroid diseases | 255 (7.1) | 0.0–15.0 | 224 (6.3) | 0.0–13.8 |
Obesity | 208 (5.8) | 0.0–34.1 | 144 (4.0) | 0.0–30.1 |
Hepatopathy | 125 (3.5) | 0.0–10.2 | 109 (3.0) | 0.0–8.9 |
Other | 556 (15.5) | 7.2–29.7 | 489 (13.7) | 6.4–29.7 |
Urogenital | 665 (18.6) | 0.0–45.1 | 591 (16.5) | 0.0–44.3 |
Prostatic hypertrophy | 432 (12.1) | 0.0–24.8 | 385 (10.8) | 0.0–24.0 |
Nephropathy | 129 (3.6) | 0.0–15.9 | 115 (3.2) | 0.0–15.9 |
Other | 147 (4.1) | 0.0–15.0 | 134 (3.7) | 0.0–14.6 |
Blood and immunity | 229 (6.4) | 0.0–15.4 | 187 (5.2) | 0.0–15.4 |
Haematopoietic disorders | 63 (1.8) | 0.0–4.5 | 54 (1.5) | 0.0–4.5 |
Allergy | 51 (1.4) | 0.0–2.6 | 37 (1.0) | 0.0–2.5 |
Immunodeficiency | 9 (0.3) | 0.0–0.9 | 8 (0.2) | 0.0–0.9 |
Other | 118 (3.3) | 0.0–11.0 | 97 (2.7) | 0.0–11.0 |
Other | 1578 (44.1) | 17.6–79.3 | 1371 (38.3) | 17.6–76.4 |
Osteoporosis | 485 (13.5) | 0.0–23.2 | 438 (12.2) | 0.0–22.0 |
Solid tumour (excluding C34) | 304 (8.5) | 2.6–25.2 | 261 (7.3) | 0.0–24.4 |
Depression | 287 (8.0) | 0.0–31.3 | 251 (7.0) | 0.0–30.5 |
Psoriasis | 63 (1.8) | 0.0–6.9 | 54 (1.5) | 0.0–6.5 |